Homepage Featured News
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY™ platform for biomarker discovery, therapy selection and response monitoring
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
The final module of its premarket approval (PMA) application for Shield™, Guardant Health’s blood test to screen for colorectal cancer (CRC).
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy
Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic development
Musa Tariq Joins Guardant Health Board of Directors
Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands.
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
Shield ™ blood test will be used to evaluate whether blood test option improves adherence to colorectal cancer screening recommendations in medically underserved populations at Federally Qualified Health Centers
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Guardant360 CDx test is now covered under UHC commercial policies for all FDA-approved biomarker confirmation indications in patients with advanced or metastatic breast or non-small cell lung cancer
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
A strategic collaboration on the development, regulatory approval and commercialization of the Guardant360® CDx and Guardant360TissueNext™ assays as companion diagnostics for taletrectinib in the United States and European Union.
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Guardant Health will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
Guardant GalaxyTM, a suite of advanced analytical technologies developed internally and through outside partnerships to enhance the performance and clinical utility of Guardant Health’s portfolio of cancer tests and to power the next generation of biomarker and drug discovery.
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
The U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant), a nonsteroidal selective estrogen receptor degrader to be commercialized by Stemline Therapeutics, Inc., a wholly-owned subsidiary of Menarini Group.